DLL3/CD3 bispecific antibody: mechanism of action

Our delta-like canonical Notch ligand 3/cluster of differentiation 3 (DLL3/CD3) antibody is a bispecific T-cell engager directed against tumours expressing DLL3. The bispecific antibody functions as a bridge between tumour cells and cytolytic T cells, directing their activity selectively to DLL3-expressing tumours. The first-in-human study of this DLL3/CD3 bispecific antibody is planned to commence in 2020. This is an investigational compound and has not been approved. Its safety and efficacy has not been established. For more information visit: https://www.boehringer-ingelheim.com/... Click on the red button above to subscribe to our YouTube channel. Taking cancer on through the power of the body’s immune system offers exciting potential. We are driven to develop first-in-class immuno-oncology treatments with breakthrough potential. Our focus, passion and commitment, combined with our strong collaborations, will help us transform expectations, give hope to more patients and help win the fight against cancer.